Ayelet David (Inventor), Gonen Ashkenasy (Inventor), Yosi Shamay (Inventor), Ayelet David (Inventor), Gonen Ashkenasy (Inventor), Yosi Shamay (Inventor)

Research output: Patent


The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells.

Original languageEnglish
Patent numberUS2015056157
IPCG01N 33/ 50 A I
Priority date19/08/14
StatePublished - 26 Feb 2015


Dive into the research topics of 'VASCULAR DELIVERY SYSTEMS'. Together they form a unique fingerprint.

Cite this